WithdrawnPhase 2

Adjunctive CB1 Agonist Nabilone in Inpatients With Active Suicidal Ideation

Stopped: The study was stopped due to drug unavailability. The drug is unavailable because production was discontinued in the US.

United States0Started 2021-04

Plain-language summary

Suicide is a major crisis worldwide with rates projected to continue to increase. There is currently a dearth of novel pharmacologic treatment options for suicide available on the market. The endocannabinoid system has been recently shown to be associated with mood disorders including suicidality. The aim of the study is to determine whether treatment with Nabilone is capable of reducing suicidal ideation in adults after 3 days.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Able to provide written informed consent * Current suicidal ideation * Columbia Suicide Severity Rating Scale (CSSRS) score of ≥ 4 and Scale for Suicide Ideation (SSI) first 5 items, score of ≥4 * Current major depressive episode as evidenced by MADRS score ≥ 20 Exclusion Criteria: * Current diagnosis of a Diagnostic and Statistical Manual V (DSM-V) psychotic disorder, psychotic symptoms, or personality disorder. * Recent (\<72 hrs) use of illicit substances * Comorbid substance use disorder diagnosis * Urine drug screen (UDS) positive for tetrahydrocannabinol (THC) * Pregnant or nursing women * Unstable medical condition

What they're measuring

Change in Suicidal Ideation and Behavior as assessed by an abbreviated version of the Columbia-Suicide Severity Rating Scale (CSSRS)

Timeframe: baseline, day 3

Trial details

NCT IDNCT04807829

SponsorThe University of Texas Health Science Center, Houston

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-04

View on ClinicalTrials.gov More Suicidal Ideation trials